Barriers to access to hepatitis C treatment

Hepatitis C virus (HCV) is a major cause of chronic liver disease worldwide. Only 1%–30% of patients in need of treatment may get it. In recent years, the availability of direct-acting antiviral agents (DAA) has been an important advancement in treating HCV infection. However, due to cost, it is not...

Full description

Saved in:
Bibliographic Details
Main Authors: Hava Yilmaz, Esmeray Mutlu Yilmaz, Hakan Leblebicioglu
Format: Article
Language:English
Published: The Journal of Infection in Developing Countries 2016-04-01
Series:Journal of Infection in Developing Countries
Subjects:
Online Access:https://jidc.org/index.php/journal/article/view/7849
Tags: Add Tag
No Tags, Be the first to tag this record!